Quick Summary:
In an increasingly competitive global market, maneuvering the intricacies of the HIV Drugs sector can represent a significant undertaking. Our latest comprehensive market research report is designed to equip business executives like you with the vital information you need to ensure a competitive edge.
The HIV Drugs market, estimated to swell to US$44.5 Billion by 2030, offers immense opportunities for strategic positioning and growth across various segments, including Combination HIV Medicines and Integrase Inhibitors (INIs). Prospects for market penetration encompass a global landscape, with noteworthy potential in markets such as the U.S., China, Japan, Canada, Germany, and the rising Asia-Pacific region.
Our estimates come enriched with exclusive insights into 52 key competitors. This report also provides invaluable quantitative data on market presence across different regions and global competitiveness. Additionally, gain unlimited access to our digital archives, research platform, and complimentary updates for a year. Secure your strategic advantage - invest in our refined market intelligence today.
Global HIV Drugs Market to Reach $44.5 Billion by 2030
The global market for HIV Drugs estimated at US$29.6 Billion in the year 2022, is projected to reach a revised size of US$44.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2022-2030. Combination HIV Medicines, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$29 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Integrase Inhibitors (INIs) segment is readjusted to a revised 5.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.1 Billion, While China is Forecast to Grow at 8.8% CAGR
The HIV Drugs market in the U.S. is estimated at US$8.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.Select Competitors (Total 52 Featured) -
- AbbVie, Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Daiichi Sankyo Co., Ltd.
- Emcure Pharmaceuticals Pvt., Ltd.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Hetero Drugs Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ViiV Healthcare
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for HIV Drugs?
What is the growth rate of the Global Market for HIV Drugs?
What is the forecasted size of the Global Market for HIV Drugs?
Who are the key companies in the Global Market for HIV Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 164 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 29.6 Billion |
| Forecasted Market Value ( USD | $ 44.5 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie, Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Daiichi Sankyo Co., Ltd.
- Emcure Pharmaceuticals Pvt., Ltd.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Hetero Drugs Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ViiV Healthcare
